Evidence map›Paper›PMID 40468317›Full record

ArticleRespiratory research2025

HNRNPH1 promotes autophagy to inhibit the development of lung adenocarcinoma via the HSP90AB1/MAP1LC3B axis.

Rong Li, Fen Li, Qian Liu, Xu Wu, Xiaowu Tan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rong LiPulmonary and Critical Care Medicine, the Second Affiliated Hospital, University of South China, Hengyang, Hunan, China. Hengyang Medical School, University of South China, Hengyang, China.
Fen LiGeneral Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Qian LiuThe Second Affiliated Hospital, Chinaintensive Care Unit, Hengyang Medical School, University of South China, Hengyang, China.
Xu WuPulmonary and Critical Care Medicine, the Second Affiliated Hospital, University of South China, Hengyang, Hunan, China. Hengyang Medical School, University of South China, Hengyang, China. wx1048946906@126.com.
Xiaowu TanPulmonary and Critical Care Medicine, the Second Affiliated Hospital, University of South China, Hengyang, Hunan, China. Hengyang Medical School, University of South China, Hengyang, China. tanxiaowu1970@163.com.

Funding

National Key Specialty Research Program Z2023016
6 · The paper itself

Abstract

backgroundLung adenocarcinoma (LUAD) is a prevalent subtype of lung cancer (LC) whose progression is regulated by multiple genes. This study sought to find the impact and mechanism of HNRNPH1 on LUAD.

methodsThe expression and role of HSP90AB1, HNRNPH1, and autophagy-related protein MAP1LC3B in LUAD were detected. Additionally, bioinformatics analysis, silencing and overexpression techniques, and in vivo modeling were used to explore the regulatory mechanisms of these proteins in the progression of LUAD.

resultsHSP90AB1 showed high expression in LUAD and was linked to a worse prognosis. Overexpression of HSP90AB1 significantly promoted the malignant phenotype of LUAD cells and inhibited MAP1LC3B-mediated autophagy. However, overexpression of HNRNPH1 could reverse the malignant phenotype resulting from HSP90AB1 overexpression and promote MAP1LC3B-mediated autophagy by binding to HSP90AB1 mRNA and inhibiting its protein expression. Animal experiments also revealed that overexpression of HNRNPH1 could inhibit tumor progression by promoting cellular autophagy.

conclusionsWe verified the key role of HSP90AB1, HNRNPH1, and MAP1LC3B in LUAD, and revealed a possible regulatory mechanism, namely, HNRNPH1 could inhibit the development of LUAD by promoting autophagy through the HSP90AB1/MAP1LC3B axis. These findings may offer new insights for improving the treatment and prognosis of LUAD. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Adenocarcinoma of LungAutophagyHSP90 Heat-Shock ProteinsLung NeoplasmsMicrotubule-Associated ProteinsA549 CellsAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, Inbred BALB CMice, NudeXenograft Model Antitumor AssaysHSP90AB1 protein, humanHSP90 Heat-Shock ProteinsMAP1LC3B protein, humanMicrotubule-Associated ProteinsAutophagyHNRNPH1HSP90AB1Lung adenocarcinomaMAP1LC3B

Identifiers

PMID40468317
PMCPMC12139211

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.